Such spatial variations in pathway dependence—where distinct tumor regions may predominantly utilize estrogen signaling, HER2 activation, or both mechanisms—underlie the reduced neoadjuvant therapy efficacy observed in HR+/HER2+ breast cancer [6]. The gene discussed is ERBB2; the disease is neoplasm.